Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 06, 2022
Event: Notice of material breach issued to Janssen Pharmaceuticals, Inc. regarding a manufacturing services agreement for the Ad26.COV2-S vaccine.
Key Financial Metrics and Contract Value
- Original Contract Value: Approximately $480 million for the first two years of a five-year agreement.
- Estimated Termination Payments: Management estimates payments owed by Janssen upon termination to be in the range of $125 million to $420 million.
- Revenue/Profit/Cash Flow: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Events
On June 6, 2022, Emergent BioSolutions notified Janssen of a material breach of their July 2, 2020, manufacturing services agreement. The breach is attributed to:
- Failure by Janssen to provide requisite forecasts for product quantities.
- Confirmation of Janssen's intent not to purchase the minimum required quantity of the product.
- Janssen's decision to wind down the agreement before fulfilling minimum requirements.
The agreement allows for termination if a material breach is not cured within 30 days of notice. Upon termination, Janssen remains liable for payments for services related to the required minimum quantity and certain raw materials purchased prior to termination.
Outlook, Risks, and Contingencies
Management Commentary: The company asserts that Janssen is liable for payments estimated between $125 million and $420 million if the agreement is terminated. The company agrees to cease services and mitigate expenses upon notification of termination.
Risks and Contingencies: The filing includes a Safe Harbor statement noting that the estimated payment range is a forward-looking statement. Actual results may differ due to various factors, including those identified in the company's risk factors in periodic SEC reports. The outcome of the breach notice and potential termination remains contingent on the 30-day cure period and subsequent actions by Janssen.
Investor Verification Checklist
- Verify the status of the 30-day cure period following the June 6, 2022, notice of material breach.
- Confirm whether Janssen has formally terminated the agreement or initiated a cure process.
- Monitor future filings for the final determination of the payment amount within the $125 million to $420 million estimated range.
- Review the impact of this potential wind-down on the company's future revenue guidance and cash flow projections.